Sign In
Buy CRVS
$11.60
-0.0900 (-0.770%)
At Close: Jun 03, 2026
Xencor (XNCR) Receives a Buy from Mizuho Securities
02:28am, Tuesday, 18'th Feb 2020
Mizuho Securities analyst
Mara Goldstein
maintained a
Buy
rating on Xencor (
XNCR
–
Research Report
) yesterday and set a price target of
$52.00
. The company’s shares closed last Monday at $36.49
Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichm
The Week Ahead In Biotech: SMID-Cap Earnings In The Spotlight
08:22pm, Sunday, 09'th Feb 2020
Biotech stocks recovered last week along with the broader markets, which bounced back from a China coronavirus-induced sell-off. Big pharma earnings took the spotlight, with Merck & Co., Inc. (NYSE: M
Eyes On Coronavirus, Alibaba, Samsung And Overstock.com
01:38pm, Saturday, 08'th Feb 2020
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
Key events next week - healthcare
02:47pm, Friday, 07'th Feb 2020
Noteworthy events during the week of February 9 - 15 for healthcare investors.MONDAY (2/10): Global NASH Congress, London (2 days).WORLDSymposium, Orlando, FL (4 days). REGENXBIO (NASDAQ:RGNX): Phase
Arcus Biosciences (RCUS) Receives a Buy from Mizuho Securities
10:18pm, Sunday, 02'nd Feb 2020
Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Arcus Biosciences (RCUS – Research Report) today and set a
Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichm
Update: U.S. Insurtech Corvus Insurance Raises $32 Million Through Series B Funding Round Led By Telstra Ventures
02:00pm, Thursday, 09'th Jan 2020
Corvus Insurance, a U.S.-based insurtech startup, announced on Thursday it raised $32 million through its Series B funding round, which was led by Telstra Ventu
Hedge Funds Aren’t Crazy About Corvus Pharmaceuticals, Inc. (CRVS) Anymore
03:56pm, Friday, 20'th Dec 2019
With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the second
Read This Before Selling Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Shares
11:28am, Tuesday, 17'th Dec 2019
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichm
Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichm
BURLINGAME, Calif., Nov. 07, 2019 -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of.
Corvus Pharmaceuticals to Present at the 28th Annual Credit Suisse Healthcare Conference
01:30pm, Tuesday, 05'th Nov 2019
BURLINGAME, Calif., Nov. 05, 2019 -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of.
Corvus Pharmaceuticals to Webcast Investor & Analyst Event on November 8, 2019
01:30pm, Monday, 04'th Nov 2019
Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichm
